Mucolytic Focus Target COPD, cystic fibrosis and asthma with inhaled mucolytic therapy (AER-01) to address mucus overproduction and plugs, presenting a clear clinical need for respiratory care buyers and specialty distributors.

Clinical Stage Advantage Early-stage clinical candidate with demonstrated safety and efficacy signals and a clear regulatory path, offering a partnering or investment opportunity for pharma companies seeking pipeline diversification and in-licensing potential.

Strategic Partnerships Research origins from UCSF and European labs plus NIH funding highlight a strong science pedigree and potential for co-development or sponsored research deals with large biopharma or contract research organizations.

Funding Momentum Recent multi-million Series A funding and ongoing capital needs indicate readiness for scale-up collaborations, manufacturing partnerships, and distribution channel discussions with specialty pharma and biopharma investors.

Early Commercial Readiness Clinical API ready and initial trial infrastructure established, enabling accelerated discussions for supply agreements, manufacturing transfers, and regional licensing in COPD and muco-obstructive disease markets.